{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:33:09Z","timestamp":1794256389802,"version":"4.9.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Bergen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Assess the prevalence of off-label psychotropic medication use in paediatric and adolescent outpatients, and to identify the most frequently prescribed drugs for various psychiatric conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cross-sectional study was performed using data from the Norwegian Prescription Database (NorPD) and responses to an electronic survey distributed to child and adolescent psychiatrists across Norway. The NorPD data used in this study was collected from January 1, 2019, through December 31, 2019. The electronic survey was sent out in January 2021 and was active until March 2021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We analysed a total of 55,066 prescriptions, and identified that 55% of these were off-label. When medications for hyperkinetic disorders were excluded, the percentage of off-label prescriptions surged to 95%. Medicines for hyperkinetic disorder had the lowest proportion of off-label use (1%), while the medication class with the most off-label use was other agents, e.g. mood stabilising agents and hypnotics and sedatives (100%). The medicines that were most commonly prescribed were methylphenidate for hyperkinetic disorder, quetiapine for schizophrenia and bipolar disorder, sertraline for depressive disorder and anxiety\/obsessive-compulsive disorder.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The off-label usage of psychotropic medications in children and adolescents is prevalent across most psychiatric disorders, with the exception of hyperkinetic disorder. This finding underlines the necessity for ongoing monitoring and assessment of prescription practices, as well as additional research into the safety and efficacy of psychotropic medications in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12888-025-07176-6","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:07:00Z","timestamp":1753877220000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Off-label use of psychotropic drugs in youth"],"prefix":"10.1186","volume":"25","author":[{"given":"Haakon Gravanti","family":"Rosland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gro Janne","family":"Wergeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4775-5892","authenticated-orcid":false,"given":"Lone","family":"Holst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"7176_CR1","unstructured":"World Health Organization: WHO. (2024, October 10). Mental health of adolescents. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/adolescent-mental-health."},{"key":"7176_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1753-2000-2-24","volume":"2","author":"JM Zito","year":"2008","unstructured":"Zito JM, Derivan AT, Kratochvil CJ, Safer DJ, Fegert JM, Greenhill LL. Off-label psychopharmacologic prescribing for children: history supports close clinical monitoring. Child Adolesc Psychiatry Ment Health. 2008;2:24.","journal-title":"Child Adolesc Psychiatry Ment Health"},{"issue":"3","key":"7176_CR3","doi-asserted-by":"publisher","first-page":"e0248864","DOI":"10.1371\/journal.pone.0248864","volume":"16","author":"T B\u00f8e","year":"2021","unstructured":"B\u00f8e T, Heiervang ER, Stormark KM, Lundervold AJ, Hysing M. Prevalence of psychiatric disorders in Norwegian 10-14-year-olds: results from a cross-sectional study. PLoS One. 2021;16(3):e0248864. https:\/\/doi.org\/10.1371\/journal.pone.0248864.","journal-title":"PLoS One"},{"issue":"6","key":"7176_CR4","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00787-014-0631-y","volume":"24","author":"H-C Steinhausen","year":"2015","unstructured":"Steinhausen H-C. Recent international trends in psychotropic medication prescriptions for children and adolescents. Eur Child Adolesc Psychiatry. 2015;24(6):635\u201340.","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"7176_CR5","doi-asserted-by":"crossref","unstructured":"Barczyk ZA, Rucklidge JJ, Eggleston M, Mulder RT. (2019). Psychotropic Medication Prescription Rates and Trends for New Zealand Children and Adolescents 2008\u20132016. Journal of Child and Adolescent Psychopharmacology.","DOI":"10.1089\/cap.2019.0032"},{"key":"7176_CR6","unstructured":"Recommendations. Depression in children and young people: Identification and management: Guidance. NICE. (Published June 25, 2019; Accessed November 28, 2023). Available from: https:\/\/www.nice.org.uk\/guidance\/ng134\/chapter\/Recommendations."},{"key":"7176_CR7","unstructured":"Alvarez EA, Puliafico MA, Leonte APPHD, Glazier KGL, PHD, Albano AMA, Marie PHD. (2021, February 2). Psychotherapy for anxiety disorders in children and adolescents. UpToDate. https:\/\/www.uptodate.com\/contents\/psychotherapy-for-anxiety-disorders-in-children-and-adolescents. Accessed 20\u00a0Dec 2022."},{"key":"7176_CR8","unstructured":"Bonin LB, PHD, Moreland CSM. DO. (2022, September 10). Overview of prevention and treatment for pediatric depression. UpToDate. https:\/\/www.uptodate.com\/contents\/overview-of-prevention-and-treatment-for-pediatric-depression?search=depressive%20disorder%20children&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1. Accessed 20\u00a0Dec 2022."},{"key":"7176_CR9","unstructured":"American Psychological Association. (2019). Clinical practice guideline for the treatment of depression across three age cohorts. Retrieved from https:\/\/www.apa.org\/depression-guideline."},{"key":"7176_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/fpsyt.2018.00004","volume":"9","author":"D David","year":"2018","unstructured":"David D, Cristea I, Hofmann SG. Why cognitive behavioral therapy is the current gold standard of psychotherapy. Front Psychiatry. 2018;9:4.","journal-title":"Front Psychiatry"},{"key":"7176_CR11","unstructured":"Obtaining an EU marketing authorisation, step-by-step. Published 2022, October 27; Retrieved November 28, 2023. European Medicines Agency. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/marketing-authorisation\/obtaining-eu-marketing-authorisation-step-step."},{"key":"7176_CR12","unstructured":"Who we are. Published 2022, June 7; Retrieved November 28, 2023. European Medicines Agency. Available from: https:\/\/www.ema.europa.eu\/en\/about-us\/who-we-are."},{"key":"7176_CR13","unstructured":"Center for Drug Evaluation and Research. (n.d.). Drugs. (Published n.d; Retrieved November 28, 2023) U.S. Food And Drug Administration. Available from: https:\/\/www.fda.gov\/drugs."},{"key":"7176_CR14","unstructured":"Retrieved. November 28, 2023. Statens Legemiddelverk. Available from: https:\/\/legemiddelverket.no\/english\/about-us."},{"key":"7176_CR15","unstructured":"Ema. Off-label use. Published n.d.; Retrieved November 28, 2023. European Medicines Agency. Available from: https:\/\/www.ema.europa.eu\/en\/glossary\/label-use."},{"key":"7176_CR16","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s00702-022-02542-0","volume":"129","author":"G Hefner","year":"2022","unstructured":"Hefner G, Wolff J, Toto S, et al. Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry. J Neural Transm. 2022;129:1353\u201365. https:\/\/doi.org\/10.1007\/s00702-022-02542-0.","journal-title":"J Neural Transm"},{"key":"7176_CR17","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/jphp.12581","volume":"69","author":"A Teigen","year":"2017","unstructured":"Teigen A, Wang S, Truong BT, Bjerknes K. Off-label and unlicensed medicines to hospitalised children in Norway. J Pharm Pharmacol. 2017;69:432\u20138. https:\/\/doi.org\/10.1111\/jphp.12581.","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"7176_CR18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.4103\/2229-3485.106403","volume":"4","author":"SB Bavdekar","year":"2013","unstructured":"Bavdekar SB. Pediatric clinical trials. Perspect Clin Res. 2013;4(1):89\u201399.","journal-title":"Perspect Clin Res"},{"key":"7176_CR19","unstructured":"Paediatric Regulation. Published May 20. 2021; Retrieved November 28, 2023. European Medicines Agency. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/paediatric-medicines\/paediatric-regulation."},{"key":"7176_CR20","unstructured":"Paediatric investigation plans. Published July 7, 2022; Retrieved November 28, 2023. European Medicines Agency. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/paediatric-medicines\/paediatric-investigation-plans."},{"issue":"1","key":"7176_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1001\/jamainternmed.2015.6058","volume":"176","author":"T Eguale","year":"2016","unstructured":"Eguale T, Buckeridge DL, Verma A, Winslade NE, Benedetti A, Hanley JA, Tamblyn R. Association of off-label drug use and adverse drug events in an adult population. JAMA Intern Med. 2016;176(1):55.","journal-title":"JAMA Intern Med"},{"issue":"9","key":"7176_CR22","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1089\/cap.2016.0202","volume":"27","author":"C Schr\u00f6der","year":"2017","unstructured":"Schr\u00f6der C, D\u00f6rks M, Kollhorst B, Blenk T, Dittmann RW, Garbe E, Riedel O. Extent and risks of antipsychotic off-label use in children and adolescents in Germany between 2004 and 2011. J Child Adolesc Psychopharmacol. 2017;27(9):806\u201313.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"7176_CR23","unstructured":"Rosenberg DR.Published MD. October 12, 2022; Retrieved November 28, 2023. Treatment of obsessive-compulsive disorder in children and adolescents. UpToDate. Available from: https:\/\/www.uptodate.com\/contents\/treatment-of-obsessive-compulsive-disorder-in-children-and-adolescents#H19049169."},{"key":"7176_CR24","unstructured":"Skirbekk B, Kristensen H. (2019). Angstlidelser. Norwegian Association of Doctors. Available from. Angstlidelser (legeforeningen.no)."},{"issue":"1","key":"7176_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00787-015-0699-z","volume":"25","author":"ES Nielsen","year":"2016","unstructured":"Nielsen ES, Hellfritzsch M, S\u00f8rensen MJ, Rasmussen H, Thomsen PH, Laursen T. Off-label prescribing of psychotropic drugs in a Danish child and adolescent psychiatric outpatient clinic. Eur Child Adolesc Psychiatry. 2016;25(1):25\u201331.","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"7176_CR26","unstructured":"EMA. ATC code. Published n.d.; Retrieved November 28. 2023. European Medicines Agency. Available from. https:\/\/www.ema.europa.eu\/en\/glossary\/atc-code#:~:text=The%20Anatomical%20Therapeutic%20Chemical%20code,on%20and%20how%20it%20works."},{"key":"7176_CR27","unstructured":"Norwegian Prescription Database. Published September 7. 2015; Retrieved November 28, 2023. Norwegian Institute of Public Health. Available from: https:\/\/www.fhi.no\/en\/hn\/health-registries\/norpd\/norwegian-prescription-database\/."},{"key":"7176_CR28","unstructured":"About Helfo. Published n.d.; Retrieved June 5. 2023. Helfo. Available from: https:\/\/www.helfo.no\/english\/about-helfo."},{"key":"7176_CR29","unstructured":"Abilify. 2009, June 4. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/abilify-epar-product-information_no.pdf. Accessed 22\u00a0Aug 2023."},{"key":"7176_CR30","unstructured":"Downloading IBM, Retrieved. May 15, 2023. Available from: https:\/\/www.ibm.com\/support\/pages\/downloading-ibm-spss-statistics-25."},{"issue":"5","key":"7176_CR31","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1097\/JCP.0000000000000559","volume":"36","author":"JV Bra\u00fcner","year":"2016","unstructured":"Bra\u00fcner JV, Johansen LM, Roesbjerg T, Pagsberg AK. Off-label prescription of psychopharmacological drugs in child and adolescent psychiatry. J Clin Psychopharmacol. 2016;36(5):500\u20137.","journal-title":"J Clin Psychopharmacol"},{"key":"7176_CR32","unstructured":"ADHD. (Published May 04, 2022: Retrieved June 6, 2023) Helsedirektoratet. Available from: https:\/\/www.helsedirektoratet.no\/retningslinjer\/adhd."},{"key":"7176_CR33","unstructured":"Recommendations| Attention deficit hyperactivity disorder: diagnosis and management| Guidance| NICE. Published March 14, 2018; Retrieved May 15, 2023. Available from: https:\/\/www.nice.org.uk\/guidance\/ng87\/chapter\/Recommendations."},{"key":"7176_CR34","unstructured":"Statens Legemiddelverk (Published February 1. 2021; Retrieved June 6, 2023). Fontex. Legemiddes\u00f8k. Available from: https:\/\/www.legemiddelsok.no\/_layouts\/15\/Preparatomtaler\/Spc\/1995-03722.pdf."},{"key":"7176_CR35","unstructured":"Psykofarmaka\u2013 Bruk hos barn og unge. (Published September 07. 2022; Retrieved June 6, 2023) Helsedirektoratet. Available from: https:\/\/www.helsedirektoratet.no\/faglige-rad\/psykofarmaka-bruk-hos-barn-og-unge."},{"issue":"9","key":"7176_CR36","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1007\/s00787-022-01996-7","volume":"32","author":"T Widding-Havneraas","year":"2023","unstructured":"Widding-Havneraas T, Markussen S, Elwert F, et al. Geographical variation in ADHD: do diagnoses reflect symptom levels? Eur Child Adolesc Psychiatry. 2023;32(9):1795\u2013803.","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"2","key":"7176_CR37","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/s2215-0366(23)00345-0","volume":"11","author":"S Cortese","year":"2024","unstructured":"Cortese S, Purper-Ouakil D, Apter A, Arango C, Baeza I, Banaschewski T, Buitelaar J, Castro-Fornieles J, Coghill D, Cohen D, Correll CU, Gr\u00fcnblatt E, Hoekstra PJ, James A, Jeppesen P, Nagy P, Pagsberg AK, Parellada M, Persico AM, Moreno C. Psychopharmacology in children and adolescents: unmet needs and opportunities. Lancet Psychiatry. 2024;11(2):143\u201354. https:\/\/doi.org\/10.1016\/s2215-0366(23)00345-0.","journal-title":"Lancet Psychiatry."}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-07176-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-025-07176-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-07176-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T07:43:11Z","timestamp":1757317391000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-025-07176-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7176"],"URL":"https:\/\/doi.org\/10.1186\/s12888-025-07176-6","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"2 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the appropriate ethics committee (Norwegian Centre for Research Data (SKIL, formerly NSD as of study application)) and consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Data obtained from all participants have been consented for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"739"}}